protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Company profile
Ticker
PLX
Exchange
Website
CEO
Dror Bashan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EMBASSY ACQUISITION CORP, ORTHODONTIX INC
SEC CIK
Corporate docs
IRS number
650643773
PLX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
14 Mar 24
8-K
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
14 Mar 24
8-K
Protalix BioTherapeutics Issues 2024 Letter to Stockholders
26 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
6 Nov 23
8-K
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
12 Sep 23
S-8
Registration of securities for employees
11 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jul 23
Transcripts
PLX
Earnings call transcript
2023 Q3
6 Nov 23
PLX
Earnings call transcript
2023 Q2
7 Aug 23
PLX
Earnings call transcript
2023 Q1
4 May 23
PLX
Earnings call transcript
2022 Q4
27 Feb 23
PLX
Earnings call transcript
2022 Q3
14 Nov 22
PLX
Earnings call transcript
2022 Q2
15 Aug 22
PLX
Earnings call transcript
2022 Q1
16 May 22
PLX
Earnings call transcript
2021 Q4
31 Mar 22
PLX
Earnings call transcript
2021 Q3
15 Nov 21
PLX
Earnings call transcript
2021 Q1
16 Aug 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.41 mm | 20.41 mm | 20.41 mm | 20.41 mm | 20.41 mm | 20.41 mm |
Cash burn (monthly) | 9.26 mm | (no burn) | 629.00 k | (no burn) | 2.30 mm | 627.00 k |
Cash used (since last report) | 64.08 mm | n/a | 4.35 mm | n/a | 15.89 mm | 4.34 mm |
Cash remaining | -43.68 mm | n/a | 16.05 mm | n/a | 4.52 mm | 16.07 mm |
Runway (months of cash) | -4.7 | n/a | 25.5 | n/a | 2.0 | 25.6 |
Institutional ownership, Q2 2023
18.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 67 |
Opened positions | 65 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 16.20 bn |
Total shares | 13.82 mm |
Total puts | 131.00 k |
Total calls | 671.70 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Nacht Marius | 2.82 mm | $0.00 |
BLK Blackrock | 2.64 mm | $5.28 bn |
Dexcel Pharma Technologies | 2.03 mm | $4.56 mm |
STT State Street | 731.24 k | $1.46 bn |
Renaissance Technologies | 659.30 k | $1.32 mm |
Marshall Wace | 562.14 k | $1.12 bn |
Geode Capital Management | 552.37 k | $1.10 bn |
NTRS Northern Trust | 362.91 k | $725.83 mm |
National Bank of Canada | 303.80 k | $559.79 mm |
Jane Street | 276.08 k | $552.16 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Oct 23 | Dror Bashan | Common Stock | Buy | Acquire P | No | No | 1.41 | 16,129 | 22.74 k | 132,516 |
19 Oct 23 | Dror Bashan | Common Stock | Buy | Acquire P | No | No | 1.4 | 48,387 | 67.74 k | 116,387 |
29 Sep 23 | Boudes Pol F | Stock Options Common Stock | Grant | Acquire A | No | No | 1.66 | 61,676 | 102.38 k | 61,676 |
29 Sep 23 | Melincoff Gwen A | Stock Options Common Stock | Grant | Acquire A | No | No | 1.66 | 61,676 | 102.38 k | 61,676 |
29 Sep 23 | Amos Bar-Shalev | Stock Options Common Stock | Grant | Acquire A | No | No | 1.66 | 61,676 | 102.38 k | 61,676 |
29 Sep 23 | Zvi Shmuel Ben | Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 61,676 | 102.38 k | 61,676 |